Pfizer has signed one of the year’s largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China’s Innovent Biologics.
The antibody–drug conjugate field arrives at ASCO 2026 in a fundamentally different shape. This Synopulse pre-conference briefing maps the five catalysts, 16+ assets, and strategic themes that will reshape the competitive landscape.
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.
While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days.
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
The EU’s Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.